SELECT PUBLICATIONS
Alberts SR et al. Systemic capecitabine and oxaliplatin administered with hepatic arterial
infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal
metastases (M-CRC) confined to the liver: A North Central Cancer Treatment Group
(NCCTG) phase II Intergroup trial. Proc ASCO 2006;Abstract 3525.
Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the
Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, f luorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract
DeGramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international
randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.
Fuchs C et al. A randomized trial of first-line irinotecan/f luoropyrimidine combinations
with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc ASCO
2006;Abstract 3506.
Hochster HS et al. Results of the TREE-2 cohort: Safety, tolerability, and efficacy of
bevacizumab added to three oxaliplatin/f luoropyrimidine regimens as first-line treatment
of metastatic colorectal cancer. Proc ASCO 2006;Abstract 244.
Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/
fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer
(mCRC): TREE 1 & 2 Studies. Proc ASCO 2005;Abstract 3515.
Maindrault-Goebel F et al. OPTIMOX2, a large randomized phase II study of maintenance
therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with
metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.
Saltz LB et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin
alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc ASCO
2004;Abstract 3500.
Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with
oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR
study. J Clin Oncol 2006;24:394-400. Abstract
Vauthey J-N et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-
day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-
72. Abstract
